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TauAlzheimer's disease is characterized by the accumulation of amyloid-β (Aβ) and Tau in the brain. In mature
neurons, Tau is concentrated in the axon and found at lower levels in the dendrite where it is required for
targeting Fyn to the spines. Here Fyn mediates Aβ toxicity, which is vastly abrogated when Tau is either deleted
or a truncated form of Tau (Tau1-255) is co-expressed. Interestingly, MAP2, a microtubule-binding protein with
mainly dendritic localization that shares Fyn-binding motifs with Tau, does not mediate Aβ's synaptic toxicity
in the absence of Tau. Herewe show in hippocampal neurons that endogenous Tau enters the entire spine, albeit
at low levels, whereas MAP2 only enters its neck or is restricted to the dendritic shaft. Based on an extensive
mutagenesis study, we also reveal that the spine localization of Tau is facilitated by deletion of the
microtubule-binding repeat domain. When distinct phosphorylation sites (AT180–T231/S235, 12E8–S262/
S356, PHF1–S396/S404) were pseudophosphorylated (with glutamic acid, using alanine replacements as
controls), Tau targeting to spines was markedly increased, whereas the pseudophosphorylation of the late
phospho-epitope S422 had no effect. In determining the role physiological Fyn has in the spine localization of
Tau, we found that neither were endogenous Tau levels reduced in Fyn knockout compared with wild-type
synaptosomal brain fractions nor was the spine localization of over-expressed pseudophosphorylated or P301L
Tau. This demonstrates that although Fyn targeting to the spine is Tau dependent, elevated levels of phosphorylated
Tau or P301L Tau can enter the spine in a Fyn-independent manner.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Alzheimer's disease (AD), as themost common formof dementia [2],
is characterized by two hallmark lesions, plaques that contain the
amyloid-β (Aβ) peptide as their major constituent, and neuroﬁbrillary
tangles that are mainly composed of heavily phosphorylated forms of
the microtubule-associated protein (MAP) Tau [15]. Tau is an unusual
protein because it contains 80 serine and threonine residues as well as
5 tyrosine residues [7]. More than a dozen of these sites are already
phosphorylated under physiological conditions, although to a varying
degree. In AD, Tau is hyperphosphorylated, which means that some of
these residues display increased phosphorylation, whereas others are
de novo phosphorylated [28]. To date, most research has focused on
serine/threonine- rather than tyrosine-directed phosphorylation,; FTD, frontotemporal dementia;
indingrepeat;PSD,postsynaptic
icroscopy
g Dementia Research (CJCADR),
land, St Lucia Campus, Brisbane,
. This is an open access article underassisted by the early availability of antibodies that recognize distinct
phosphorylated serine and threonine epitopes of Tau.
Tau is up-regulated during neuronal development. The fetal form
of Tau is initially distributed evenly in the cell body and neurites
(Fig. 1A–H). When axons emerge and neurons become polarized, Tau
becomes enriched in axons. In mammalian neurons, this axonal sorting
takes placewithin 1–2weeks [41]. In mature neurons, under physiolog-
ical conditions, the majority of Tau is localized to the axon, whereas
MAP2, another member of the MAP family, is mainly localized to the
dendrite. However, as we have reported recently for brains of adult
mice, Tau is also localized, albeit at lower levels, to the dendrite where
it serves an important function that cannot be fulﬁlled by MAP2 [20].
Here Tau is required for the targeting of the Src kinase Fyn to dendritic
spines where Fyn phosphorylates the NMDA receptor, a prerequisite
for recruiting the postsynaptic density (95kD) protein (PSD95) into a
protein complex. This complex then mediates the excitotoxic signaling
that is triggered by Aβ, the preferential binding site of which is at the
synapse [24]. However, Tau also has a physiological role in the spine
where it is thought to participate in spine ediﬁcation [8]. Furthermore,
synaptic activation has been shown to induce the translocation of Tau
to the synaptic compartment, where it interacts with ﬁlamentous actinthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1.Tau andMAP2 segregatewith advancedprimaryneurondevelopment;when spines have formed, endogenousMAP2and Tau are both localized to dendrites, butwhereas Tau enters
the spines, MAP2 only enters the spine neck. (A–H)With advanced time in culture, primary hippocampal neurons fromwild-typemice undergo a process of compartmentalization of Tau
andMAP2 (DIV1.5, A–C, G; DIV5, D–F, H; close-ups of cell bodies inG, H). (I) At DIV20, Tau ismore concentrated in axons, whereasMAP2 is concentrated in dendrites (Tau in green;MAP2
in red, and actin in blue). (K–N) Using actin to visualize spines (K), localization reveals that unlike Tau, that enters the head of spines (indicated by arrows) (L),MAP2 only enters the neck,
although only at low frequency (M). (N) Merged image with Tau (in green), MAP2 (in red), and actin (in blue). DIV, days in vitro. Scale bar: A–F (25 μm), G, H (10 μm), I–N (2 μm).
914 D. Xia et al. / Biochimica et Biophysica Acta 1852 (2015) 913–924[13]. The same study also demonstrated that a short exposure of cortical
cultures to oligomeric Aβ induces the mislocalization of Tau into the
spines under resting conditions and abrogates its subsequent activity-
dependent synaptic translocation. Together, these ﬁndings suggest
differences in synaptic Tau dynamics depending on whether it is physi-
ologically or pathologically phosphorylated.
In the absence of Tau or when a form of Tau is expressed that accu-
mulates in the cell soma and is excluded from the dendrite (such as the255 amino acid-longΔTau that contains the projection domain but lacks
the microtubule-binding repeats; MBRs), Fyn is prevented from enter-
ing the spine, as a result of which Aβ can neither directly nor indirectly
excitotoxically signal through the NMDA receptor [20]. This ﬁnding has
resulted in several models that aim to explain how Aβ, Tau and Fyn
interact in the postsynapse to cause damage to neurons [10,19].
Fyn contains an amino-terminal Src-homology (SH) region with
acylation sites, a unique domain, an SH3 domain (with which it
915D. Xia et al. / Biochimica et Biophysica Acta 1852 (2015) 913–924interacts with PXXP motifs), an SH2 domain (with which it interacts
with phospho-tyrosine residues), an SH1/kinase domain, and a
carboxy-terminal regulatory tail [23]. Tau interacts with Fyn at least in
two ways. First, the Y18 residue of Tau is phosphorylated by Fyn, with
the phosphorylated motif interacting with Fyn via the latter's SH2 do-
main [36]. Second, Tau contains seven PXXP motifs that are localized
amino-terminal of the microtubule-binding domain and are arranged
consecutively. Of these motifs, the seventh has been found to be crucial
for the interaction with the SH3 domain of Fyn and other Src non-
receptor tyrosine kinases [3,20,27]. Interestingly, this motif is also criti-
cal for the interaction of Tau with the protein phosphatase PP2A [32].
Why themainly dendritic protein MAP2 cannot compensate for the ab-
sence of Tau in Tau knockout (TauKO) mice and target Fyn to dendritic
spines is not understood, particularly as both MAP2 and Tau efﬁciently
bind Fyn [26,32,39].
In recent years, several groups have investigated the role of Tau at
the postsynapse [10]. Aβwas found to change the phosphorylation sta-
tus of Tau and alter its subcellular localization [40,42], with a speciﬁc
role reported for the S262 epitope of Tau (a site recognized by the anti-
body 12E8) [29]. How the Tau/Fyn-interaction is regulated and the
relative role of the phospho-Y18/SH2 and PXXP/SH3 interactions are
not fully understood. It has been shown that tyrosine phosphorylation
of Tau has a role in disease progression [3], possibly by triggering
down-stream phosphorylation of serine and threonine residues. In the
present study, we expressed truncated, pseudophosphorylated and
alanine-mutated (non-phosphorylatable) forms of Tau in primary hip-
pocampal cultures from C57BL/6 wild-type and Fyn knockout (FynKO)
mice to determine what dictates the localization of Tau to the spine.
2. Materials and methods
2.1. Mouse strains and animal ethics
The mouse strains used in this study included C57BL/6, TauKO [35],
FynKO [34], and Tau transgenic pR5 mice that express the P301L muta-
tion found in familial cases of frontotemporal dementia (FTD) [11].
Animal experimentation was approved by the Animal Ethics Committee
of the University of Queensland (approval number QBI/027/12/NHMRC).
2.2. Primary culture
Hippocampal neurons from embryonic day (E) 18 wild-type or
FynKOmouse embryoswere plated onto poly-D-lysine-coated coverslips
in a 12-well plate at a density of 5,000 cells/well [12]. The platingmedi-
umwas based onNeurobasalmedium (Invitrogen), supplementedwith
5% fetal bovine serum (Hyclone), 2% B27, 2 mM Glutamax (Invitrogen),
and 50 U/ml penicillin/ streptomycin (Invitrogen). This was changed to
serum-free neurobasalmedium24h post-seeding, and half themedium
was changed twice a week.
2.3. Mutagenesis and molecular cloning
Taumutant constructs were generated by site-directedmutagenesis,
using a pENTR donor vector containing full-length human 2N4R Tau
(hTau40, 441aa) as a template. To introduce a V5 tag at the carboxy-
terminus, Gateway cloning was used, and the Tau cassette was trans-
ferred from the pENTR donor vectors into the pcDNA6.2/V5-DEST
vector, using LR clonase (Invitrogen). The following expression vectors
were generated: ΔTau (Δ256-441), ΔPXXP (Δ176-242); ΔMTB (Δ256-
367); P301L, Y18A; mutants of the AT180 epitope (T231A/S235A and
T231E/S235E); mutants of the 12E8 epitope (S262A/S356A and S262E/
S356E); mutants of the PHF1 epitope (S396A/S404A and S396E/
S404E); and mutants of the serine 422 epitope (S422A and S422E). In
addition, an additional myc-tagged construct was generated for
AT180A (T231A/S235A). For an overview of the Tau phosphorylation
sites used in this study, see Chen et al. [7]. The MAP2c-EGFP plasmidwas kindly provided by Dr. Estelle Sontag (University of Newcastle,
Australia). We thank Dr. Xiaobing Yuan (Department of Neurobiology
and Anatomy, Drexel University College of Medicine, USA) for the
EGFP-α-tubulin plasmid.
2.4. Immunocytochemistry and imaging analysis
Neurons were transfected at 18 days in vitro (DIV18) using Lipofec-
tamine 2000 (Invitrogen). To visualize endogenous Tau and MAP2, im-
ages were also taken at DIV1.5 and DIV5. A red ﬂuorescent protein
(tagRFP, in short: RFP; Evogen) expression vector was co-transfected
to visualize neurons fully, i.e., including the spines. Forty-eight hours
after the transfection, cells were washed once with PBS, ﬁxed with 4%
paraformaldehyde/4% sucrose for 10 min, permeabilized with 0.2% Tri-
ton X-100 for 10 min, then blocked for 1 h in 10% goat serum, followed
by incubation overnight at 4 °C. Primary antibodies were mouse anti-
myc (Sigma, 1:500), rabbit anti-V5 (Sigma, 1:500), rabbit anti-human
Tau (Dako, 1:500), rabbit anti-MAP2 (Millipore; 1:500), mouse anti-
Tau5 (Millipore, 1:500), and mouse anti-PSD95 (Millipore, 1:500). Sec-
ondary antibodies were Alexa Fluor (488, 555, 647)-labeled goat anti-
mouse and goat anti-rabbit IgG antibodies (Invitrogen). We further
used Alexa Fluor647-labeled phalloidin (Invitrogen) to detect actin.
RFP was co-transfected as a control. Fluorescence images were taken
with a 20 or 60× objective on a Zeiss LSM710 laser scanning confocal
microscope. Super-resolution structured illumination microscopy
(SIM) images were taken with a 60X objective on a Zeiss ELYRA PS.1
SIM/STORM microscope.
2.5. Synaptosomal preparations and western blot analysis
Synaptosomes were prepared from dissected forebrains (n = 4 for
the each genotypes) using a modiﬁed volume-adjusted method based
on a previously published protocol [20]. In brief, brain tissue was
homogenized in sucrose buffer (1 ml/60 mg tissue, 0.32 M sucrose,
1mMNaHCO3, 1mMMgCl2, and 0.5mMCaCl2) using a dounce homog-
enizer (800 rpm, 10 strokes). The brain homogenate was centrifuged at
1,400g for 10min. Two hundredmicroliters of the supernatant was col-
lected as the “whole brain lysate,” and the pellet containing cell debris
and nuclei was discarded. The remaining supernatant was then centri-
fuged at 14,000g for 20 min to obtain the crude synaptosomal fraction
in the pellet. The pellet was then re-suspended in 2 ml sucrose buffer,
layered over a discontinuous Ficoll gradient (4 ml of both 5% and 12%),
followed by centrifugation at 80,000g for 1 h (SW41 Ti Rotor, Swinging
Bucket, Beckman). A milky interface containing the synaptosomes was
recovered from the layer between the 5% and 12% Ficoll layers; this
was topped-up with sucrose buffer to 3 ml and centrifuged at 45,000g
for 25 min to pellet the synaptosomes (TLA-100 Rotor, Fixed Angle,
Beckman). Puriﬁed synaptosomes were then sequentially extracted
with buffers of increasing stringency: pH 6 (40 mM Tris–HCl, 2% Triton
X-100, 0.5 mM CaCl2), pH 8 (20 mM Tris–HCl, 1% Triton X-100), and
SDS (5% SDS) as previously described [30]. The SDS buffer extract
contains strongly PSD-associated proteins. All solutions contained pro-
tease inhibitors (Complete Protease Inhibitor Cocktail tablets, Roche)
and phosphatase inhibitors (10 mM NaF, 1 mM Na3VO4, and 2 mM
Na4P2O7, all from Sigma). All centrifugations were carried out at 4 °C.
For western blot analysis, the following primary antibodies were used:
total Tau (Dako, polyclonal, 1:5,000), Fyn (BD Biosciences, 1:2,000),
PSD95 (Millipore, 1:2,000), MAP2 (Sigma, monoclonal, 1:1,000), and
actin (monoclonal, Millipore, clone C4, 1:5,000).
2.6. Image and data analysis
Image analysis was carried out using Zen (Zeiss imaging) and Image-J
(NIH imaging) software. For each group, in three independent experi-
ments, at least 500 spines were analyzed from more than 20 neurons.
For the analysis, dendritic branches were selected from secondary
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one in the dendritic shaft were determined in the RFP channel, and also
used for the Tau channel. Furthermore, for a subset of the samples, we
determined the mean intensity in the spine as a function of the mean
intensity in the dendritic branch, followed by a Pearson correlation anal-
ysis. This single neuron analysis was done to rule out that the spine local-
ization of Tau is simply a reﬂection of higher expression levels. The
average intensity of Tau was measured in the ROI, subtracting the back-
ground of the image. The localization of the different tagged proteins to
spines was determined by obtaining the ratio of the mean intensity in
the spine to the mean intensity in the dendritic shaft for Tau, followed
by normalization of the value obtained for RFP that distributes evenly
throughout the dendrite and the spines. An unpaired t-test was used
for statistical analysis.
3. Results
3.1. Endogenous Tau enters the dendritic spine, whereas MAP2 is conﬁned
to its neck
Both Tau and MAP2 can be easily detected in primary neuronal
cultures irrespective of their phosphorylation state. This differs from
the immunohistochemical staining of wild-type mouse tissue, in
which endogenous Tau, different fromMAP2, is difﬁcult to detect possi-
bly because it is so tightly bound to microtubules that it cannot be
labeled by Tau-speciﬁc antibodies [14]. As a primary hippocampal
neuron differentiates, Tau and MAP2 begin to compartmentalize as
shown for the processes and cell bodies with images taken from
DIV1.5 (1.5 days in vitro) and DIV5 neurons, and Tau becomes enriched
in axons whereas MAP2 becomes enriched in dendrites (Fig. 1A–H). A
close-up is shown at DIV20, with Tau being concentrated in the axon
and MAP2 in the dendrite (Fig. 1I). Given the distribution of Tau and
MAP2, it is not understoodwhy the predominantly dendriticMAP2 can-
not compensate for the absence of the primarily axonal Tau in TauKO
mice, thereby targeting Fyn to dendritic spines, particularly because
both MAP2 and Tau efﬁciently bind Fyn. By analyzing DIV20 wild-type
hippocampal cultures and using actin staining via phalloidin to visualize
the spines, we found that both endogenousMAP2 and Tau are localized
to dendrites; however, whereas Tau entered the spine head, MAP2
mostly remained localized in the dendritic shaft, entering the neck ofTau
Tau (WT)
P301L
ΔTau
ΔMTB 
ΔPXXP 
Y18A
AT180A
AT180E
12E8A
12E8E
PHF1A
PHF1E
Ser422A
Ser422E
PXXP m
Δ
Y18
SH2 SH3Fyn
Fu
ll-
le
ng
th
Tr
un
ca
tio
ns
Ph
os
ph
or
yl
at
io
n
Fig. 2. Taumutation/truncation constructs. Tau constructs generated to determine the role of cr
was used as a template. This contains fourmicrotubule-binding domains (MBRs) that are indica
dependent manner, via its SH2 domain. All Tau constructs contain a short V5-tag.only 6.5 % of spines (analyzing 200 neurons) and never the spine head
(Fig. 1K–N). This might explain why MAP2 cannot compensate for Tau
in localizing Fyn to the spine head.3.2. Over-expressed MAP2 is mainly excluded from spines, whereas P301L
Tau is enriched
We next aimed to determine whether over-expression of MAP2
would target it to the spine. We also investigated how the spine
localization of Tau is affected by the presence of the P301L mutation,
by deleting functional domains of Tau, and by either introducing
pseudophosphorylation sites or over-expressing constructs in which
critical phosphorylation residues had been mutated to alanine to abro-
gate phosphorylation (Fig. 2). All constructs were generated using the
longest human Tau isoform, hTau40, as a template, and by adding a
V5-tag at the carboxy-terminus (except for MAP2c and α-tubulin that
were tagged with EGFP).
For all transfections, using triplicates, more than 500 spines were
counted from at least 20 secondary branches. We found that even full-
length MAP2c, although targeted to the dendrite, was mainly excluded
from spines, meaning that it was either not efﬁciently targeted to the
spine head or not efﬁciently retained. Thisﬁndingwas obtained by com-
paring the distribution in the spine with that in the dendritic branch,
using RFP that distributes throughout the entire cytoplasm and into
the spines for normalization (Figs. 3A and 6A). As a control, we included
EGFP-tagged α-tubulin (Fig. 3B). When full-length Tau was over-
expressed, it was targeted to dendritic spine heads at relatively low
levels compared with RFP, whereas MAP2c showed no localization at
all (Figs. 3C and 6A). Conﬁrming previous ﬁndings [17,20], P301L Tau
was found to be targeted to the spine at a ﬁve-fold higher rate than
non-mutated, wild-type Tau (P b0.001) (Figs. 3D and 6B). A Pearson
correlation analysis revealed that the increased targeting of P301L Tau
to spines is not because of an increased expression of P301L Tau com-
pared with wild-type Tau (wild-type Tau: r = 0.79, P = 0.011; P301L
Tau: r= 0.72, P= 0.015).
To obtain a higher resolution of Tau localization, structured illumina-
tion microscopy (SIM) was used. This revealed that Tau in P301L Tau
over-expressing neurons does not co-localize with PSD95 but may
instead form a scaffold that supports the PSD (Fig. 3E–G).otifs
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Fig. 3. Over-expressed MAP2 is mainly excluded from spines, whereas P301L Tau is enriched in spines. Wild-type neurons co-transfected with different V5-tagged expression constructs
together with RFP to reveal dendrites and spines. (A) When full-length MAP2 tagged with EGFP is over-expressed, it is targeted to the dendrite but excluded from spines, which are
visualized with RFP. (B) EGFP-tagged α-tubulin is included as control. (C) When full-length Tau is over-expressed, it is targeted to the dendrite but mostly excluded from spines.
(D) In contrast, P301L Tau is targeted at high levels to the spine. (E–G) Structured illumination microscopy (SIM) was used to determine that when P301L Tau is over-expressed (E) it
does not co-localize with PSD95 (F) in the spine (G, merge). A close-up is shown on the right for the area marked by a white box in G. Scale bar: 2 μm.
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binding domain
We next compared the localization of different Tau truncation
mutants to that of full-length Tau (Fig. 4A): ΔTau that comprises the
projection domain and contains the ﬁrst 255 amino acids of the Tau
protein (based on the longest human Tau isoform) (Fig. 4B), ΔMTB
that lacks the MBRs but contains the projection domain as well as the
carboxy-terminus of the protein (Fig. 4C), and ΔPXXP that lacks the
seven PXXP binding motifs, including those that interact with the SH3
domain of Fyn (Fig. 4D). By comparing the localization with that offull-length Tau, we observed a reduced localization of ΔTau to the den-
drite, with a very low signal detectable beyond the primary dendrite
(Fig. 4B). This extends previous ﬁndings obtained in vivo [20]. ΔMTB
was found to distribute as freely as RFP (P=n.s.), including into spines,
suggesting that the binding of Tau to microtubules hinders its free
distribution (Figs. 4C and 6A). The PXXP motifs of Tau are critical for
the interaction of Fyn with Tau (Fig. 2). However, we found under
conditions with physiological Fyn levels and activity that deletion of
the PXXP motifs did not cause a difference in the targeting of Tau to
the spine from that of the full-length construct (P = n.s.) (Figs. 4D
and 6).
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Fig. 4. Spine localization is facilitated by the deletion of the microtubule-binding domain. (A) When wild-type Tau is over-expressed, it distributes throughout the neuron but is mostly
excluded from the spines (see close-up, and RFP localization that was used as a positive control for spine localization). (B) ΔTau displays reduced localization to the dendrite, with a
very low signal detectable beyond the primary dendrite. (C) ΔMTB lacks the region containing the MBRs and distributes freely, including into spines. (D) Deletion of the PXXP binding
sites that interact with the SH3 domain of Fyn does not result in spine localization that is different from that of wild-type Tau. Scale bar: 20 μm.
918 D. Xia et al. / Biochimica et Biophysica Acta 1852 (2015) 913–9243.4. Pseudophosphorylation of distinct sites (AT180, 12E8, PHF1) alone is
sufﬁcient to target Tau to spines, different from the pseudophosphorylation
of the late phospho-epitope S422
Several of the “classical” phosphorylation epitopes of Tau (e.g.
AT180) are deﬁned by two amino acid residues (T231/S235), and
hence, for our study, both sites were mutated together. To assess the
role of distinct phosphorylation sites in spine localization, we generated
a series of constructs by changing serine, threonine, and tyrosine resi-
dues either to alanine (A) to prevent phosphorylation, or to negatively
charged glutamate residues (E) in order to mimic phosphorylation.
We thus over-expressed a series of Tau constructs that were tagged
at the carboxy-terminus with a V5-tag (Fig. 2): Y18A (mutating the
tyrosine residue that is phosphorylated by Fyn) (Fig. 5A), AT180A
(Fig. 5B), AT180E (Fig. 5C), 12E8A (Fig. 5D), 12E8E (Fig. 5E), PHF1A
(Fig. 5F), PHF1E (Fig. 5G), S422A (Fig. 5H), and S422E (Fig. 5I). RFPwas used to visualize the spines, with the relative quantiﬁcation
shown in Fig. 6A. A Pearson correlation analysis revealed that, e.g., the
increased targeting of AT180E Tau to spines is not because of an
increased expression of this mutant compared with that of AT180A
(AT180E Tau: r = 0.81, P = 0.008; AT180A Tau: r = 0.84, P = 0.004)
(Fig. 6C). The analysis revealed that all A mutants were precluded
from entering the spines beyond the levels found for non-mutant, full-
length Tau. Of the E mutants, all but the S422E mutant showed an
increase in spine localization that was in the order of 4- to 5.5-fold.
Together these ﬁndings indicate that (i) phosphorylation levels are
low under normal conditions, (ii) introducing a pseudophosphorylation
at one site is sufﬁcient to target Tau to the spine, and (iii) S422 behaves
differently from the other investigated phospho-epitopes, possibly
reﬂecting the fact, as shown in animal studies, that this is an epitope
that is phosphorylated relatively late in disease (i.e., when Tauﬁlaments
have already formed) [1]. The S422 site may thus have no role in
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919D. Xia et al. / Biochimica et Biophysica Acta 1852 (2015) 913–924regulating the subcellular distribution of Tau, different from Y18, T231/
S235 (AT180), S262/S356 (12E8), and S396/S404 (PHF1). The strongest
localization effect (when considering the A/E ratio) was seen for the
AT180 epitope, which was therefore analyzed further.
3.5. AT180E Tau is targeted to the spine whereas AT180A is excluded from it
Interestingly, the AT180 epitope (a site that is hyperphosphorylated
in AD) overlapswith the seventh PXXPmotif (pT231PPKS235P) that has a
role in the interaction of Tauwith both Fyn and the protein phosphatase
PP2A [32]. We co-transfected wild-type neurons with a V5-tagged
AT180E construct and a myc-tagged AT180A construct and performed
immunocytochemistry and confocal microscopy. The A and E channelswere exposed to the laser power so as to obtain an unsaturated and
comparable signal intensity in the branch, allowing for a comparison
of the signal intensity in the spine (Fig. 7). Using RFP as a marker, we
conﬁrmed that even under co-expression conditions, AT180A is mainly
excluded from spines,whereas a signiﬁcant proportion of AT180E in the
same neurons is localized to the spines.
3.6. Absence of Fyn does not abolish Tau targeting to spine
Tau has previously been shown to be required for the targeting of
Fyn to the dendritic compartment and, more speciﬁcally, the spine
[20]. To determinewhether the opposite relationship also exists, namely,
that Tau localization to spines is Fyn dependent, we determined for a
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920 D. Xia et al. / Biochimica et Biophysica Acta 1852 (2015) 913–924series of mutants with prevalent spine localization (P301L, AT180E,
12E8E, and PHF1E) whether this localization was altered compared to
wild-type neurons, when the Tau mutants were over-expressed in
FynKO primary neuronal cultures (Fig. 8A). We also included the
AT180A mutant that in wild-type neurons is mainly excluded from the
spine (Fig. 5 and 7). We found that spine localization was not affected
by deletion of Fyn. In the case of the P301L Taumutant, therewas a slight
reduction in spine localization when Fyn was absent, although the bio-
logical signiﬁcance of this ﬁnding remains to be determined (Fig. 8B).
Using biochemical methods, we have previously reported that levels
of synaptic Fyn are reduced by 73% and 62% in synaptosomal PSD95
fractions obtained from pooled hippocampi of ΔTau transgenic and
TauKO mice, respectively, compared to wild-type controls [19,20]. We
thus obtained brain extracts and synaptosomal PSD fractions by sucrose
fractionation from total forebrains of wild-type, FynKO, and P301L
mutant Tau transgenic pR5 mice and analyzed these for levels of Fyn,
Tau, MAP2, actin, and PSD95 (Fig. 9). Loading equal amounts of protein(10 μg), the analysis revealed that neither total (normalized for actin,
P = 0.75) nor synaptosomal levels (normalized for PSD95, P = 0.12)
of Tau differed when FynKO was compared with wild-type mice
(Fig. 9). While this analysis demonstrates that the absence of Fyn does
not abolish the targeting of Tau to the spines, it does not rule out that
Fyn has a role when this kinase is over-activated as is the case in AD.
We also found conﬁrming the above spine localization analyses that
whereas MAP2 was present in total extracts, it was absent from the
synaptosomal preparation.
4. Discussion
In the present study, we expressed different truncated, pseudo-
phosphorylated, and alanine-mutated forms of the microtubule-
associated protein Tau in primary hippocampal neurons to determine
what factors dictate the localization of Tau to dendritic spines, as well
as the role of Fyn in this process.We also compared the spine localization
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localized to the spine (indicated by arrows). Scale bar: 10 μm (A–D).
921D. Xia et al. / Biochimica et Biophysica Acta 1852 (2015) 913–924of both endogenous and over-expressed Tau with that of MAP2, a
microtubule-binding protein that is mainly localized to the dendritic
compartment of mature neurons.
We ﬁrst found in mature primary hippocampal cultures obtained
fromwild-typemice that endogenous Tau is targeted to the spine, albeit
at low levels. This extends our previous ﬁndings, obtained in brain
sections and by fractionation, that a small proportion of Tau is localized
to the dendritic compartment under physiological conditions [20].
Interestingly, there is evidence for brain region-speciﬁc differences in
this localization, with Hoffmann and colleagues reporting the presence
of hyperphosphorylated Tau in dendritic spiny protrusions of CA3
hippocampal neurons, but not in the dendritic spines of pyramidal
neurons of cortical layer V [16]. The same study also demonstratedthe absence of Tau from the spines of neurons in which the
somatodendritic compartment was almost completely ﬁlled with
ﬁlamentous hyperphosphorylated Tau. Although the reason for this
brain region speciﬁcity is not understood, differences in the principal
cytoskeletal elements in hippocampal versus cortical spines may
have a role. Unlike dendritic spines of cortical pyramidal neurons,
which have an actin-based cytoskeleton, the CA3 thorny excres-
cences occasionally contain microtubules [9,33]. Indeed, in our con-
focal analysis of hippocampal cultures, we found low levels of
tubulin staining in the dendritic spines (data not shown).
We next analyzed MAP2 as the “typical” dendritic representative of
the MAP family. Interestingly, MAP2 was mostly restricted to the
dendritic shaft and only occasionally entered the neck of the spine,
0 0.2 0.4 0.6 0.8 1
RFP
PHF1E
12E8E
AT180E
AT180A
P301L
Tau
WT
FynKO
*
V5 RFP Merge
Ta
u
P3
01
L
12
E8
E
PH
F1
E
AT
18
0E
AT
18
0A
A
B
Spine targeting ratio
(n > 500)
Fig. 8. Absence of Fyn does not abolish Tau targeting to spine. (A)When Tau is over-expressed in FynKO primary neuronal cultures, the localization of phospho-Taumutants does not differ
from that inwild-type neurons. (B) For each experimental group, in three independent experiments, at least 500 spineswere analyzed frommore than 20 neurons each. A slight reduction
in spine localization is seen for P301L Tau when Fyn is absent (*P b 0.05).
922 D. Xia et al. / Biochimica et Biophysica Acta 1852 (2015) 913–924whereas Tau entered the spine head. This ﬁnding is supported by the
western blot analysis, which revealed an absence of MAP2 in the
synaptosomal fraction. Together this would explain why MAP2 can-
not compensate for the absence of Tau in TauKO mice in targeting the
tyrosine kinase Fyn to dendritic spines, despite the fact that both
Tau and MAP2 share crucial binding sites for Fyn and the serine/
threonine-directed phosphatase PP2A, which both directly and indi-
rectly regulates Tau phosphorylation [21,26,32,39]. What remainsunexplained is why MAP2 does not enter the spine head. Even by
increasing the expression levels by over-expressing MAP2, no strong
staining intensity was revealed in the spine head, which indicates
that MAP2 is either not efﬁciently targeted or not efﬁciently retained.
Because MAP2 is a relatively large scaffolding protein, it might be
bound to the microtubules in the dendritic branches more tightly
than Tau, such that it that it is less dynamic and cannot be released
efﬁciently into the spine.
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FTD-linked mutant P301L Tau is efﬁciently targeted to the spine head.
This might explain why expression of this P301L mutant form of Tau
in transgenic mice, combined with Aβ, causes a particularly strong pa-
thology and early lethality [19]. Strong effects of mutant Tau on spines
have been demonstrated in several studies. For example, expression of
mutant Tau in vivo has been shown to affect spine morphology and
eventually cause spine loss [22], a phenotype that is augmented by Aβ
[4,6]. In P301S Tau mice, the fraction of thin spines was found to be
strongly reduced, whereas that of mushroom spines was found to be
increased compared to controls [16]. Another study reported that,
even at an early age, P301S Tau transgenic mice are characterized by a
lower average spine density, length, area and volume compared with
wild-type mice, concomitant with an impaired learning at this age in
the Morris water maze [38]. Together with our ﬁndings this reveals
that FTD mutant forms of Tau accumulate in the spine, which results
in morphological changes and, subsequently, spine loss.
Our hippocampal primary culture study also revealed that a mutant
form of Tau that only comprises the projection domain (ΔTau) does not
travel efﬁciently beyond the primary dendrite, supporting previous
ﬁndings of dendritic exclusion of ΔTau [20,37]. A second deletion con-
struct, ΔMTB, lacked the MBRs but contained the projection domain as
well as the carboxy-terminus. This form of Tau was found to distribute
freely, including into the spines, suggesting that trapping of Tau by
binding to microtubules, the major interaction partner of Tau [31],
hinders its free distribution throughout the neuron. When we deleted
the PXXP motifs of Tau (a domain retained in the ΔTau mutant and
required for interaction with the SH3 domain of Fyn), the localization
of this construct to spines did not differ from that of wild-type Tau.
We had expected that the spine targeting ratio would be further
reduced but because this ratio is already low for wild-type Tau our
method may not have been sensitive enough to reveal a difference.
Although truncation of Tau is increasingly being shown to have a
role in pathogenesis [43], phosphorylation remains an important post-
translational modiﬁcation of Tau, and hyperphosphorylated Tau has a
critical role in AD pathogenesis. In our mutagenesis study, we showed
that Tau is massively targeted to the spine when the AT180, 12E8, and
PHF1 phospho-epitopes are pseudophosphorylated, using alaninemutant forms as a control. Targeting occurred to a similar degree as
for the P301Lmutant. Interestingly, the S422 epitope behaved different-
ly, as both the A and the Emutants revealed the sameweak localization
to spines.We deliberately did not use GFP-tagged versions of Tau, aswe
have found that tagging TauwithGFP instead of V5 abrogates the exclu-
sion of spine localization seen for V5-tagged wild-type Tau (data not
shown). Hoover and colleagues, in contrast, used GFP-tagged Tau for
expression and in addition expressed the shorter human 0N4R
isoform of Tau [17], whereas we expressed the longest isoform, 2N4R,
tagged with V5. In the former study, 14 serine and threonine residues
were simultaneously changed to either alanine (termed AP), or gluta-
mate (termed E14), resulting in an approximately four-fold increase
in the spine localization of E14 Tau and a four-fold decrease in the local-
ization of AP compared to wild-type Tau. In our study, we refrained
from mutating 14 sites simultaneously and rather mutated individual
sites, althoughwe had previously generated transgenicmice expressing
E10-mutated Tau [18]. Our approach of mutating single phospho-
epitopes allowed us to demonstrate that not all sites mediate spine
localization equally (AT180, 12E8, and PHF1 do, whereas S422 does
not), and to show that introducing a single pseudophosphorylation
epitope is sufﬁcient to target Tau efﬁciently to the spine. One would
conclude that in primary hippocampal neurons Tau is normally not
highly phosphorylated because, if it were, phosphorylation at any
epitope that had not been mutated to alanine should overcome the
exclusion conferred to these mutant forms as far as spine localization
is concerned. Interestingly, the S422E mutant is not efﬁciently targeted
to the spine nor does its localization differ from that of the A mutant,
suggesting that phosphorylation of this epitope has no role in subcellu-
lar Tau targeting. This is supported by the notion that this epitope is
only phosphorylated under pathological conditions, with evidence
from animal studies suggesting that this site is phosphorylated only
when Tau ﬁlaments have formed, i.e., relatively late in the AD disease
process [1].
We have previously shown that Tau is critically required to target
Fyn to dendritic spines where this kinase phosphorylates the NMDA
receptor, a prerequisite for recruiting PSD95 into a protein complex
that then mediates the excitotoxic signaling triggered by Aβ [20]. In
our study, we therefore aimed to determine whether Fyn has a role in
924 D. Xia et al. / Biochimica et Biophysica Acta 1852 (2015) 913–924targeting endogenous Tau to the synaptosomal compartment. We
found that the absence of Fyn did not abolish spine targeting of Tau.
With Fyn activation having a prominent role in AD [5], our study does,
however, not imply that Fyn has no role in phosphorylating and
targeting of Tau in a pathological context. How Tau is localized in the
presence of over-activated Fyn has not been addressed in our study.
Also, as far as the interaction between Fyn and Tau are concerned, it
remains to be determined whether Tau and Fyn form a complex when
traveling into the spine orwhether their effect ismediated independent
of a direct interaction. Possible scenarios as to how these twomolecules
might interact have been discussed previously [25].
5. Conclusion
In conclusion, we have shown that endogenous Tau and MAP2
display differences in spine localization, with Tau entering the spine
head, whereas MAP2 only enters the neck and does so infrequently.
We have also revealed a crucial role for theMBRdomain in the targeting
of Tau to the spine and have further demonstrated that spine targeting
depends on distinct phosphorylation sites and can occur independent of
Fyn. This does not rule out, that in the presence of activated Fyn, Tau's
targeting to the dendritic spine is modulated.
Acknowledgments
This study was supported by the Estate of Dr. Clem Jones AO, the
State Government of Queensland, and by grants from the Australian
Research Council [DP13300101932] and the National Health and
Medical Research Council of Australia [APP1037746 and APP1003150]
to JG. We thank Gerhard Leinenga for generating the AT180A and
AT180Emutants used in this study, Tishila Palliyaguru for expert techni-
cal assistance, Dr. Victor Anggono for advice on neuronal culture, Trish
Hitchcock and the animal staff for animal care, and Rowan Tweedale
for critically reading the manuscript.
References
[1] B. Allen, et al., Abundant tau ﬁlaments and nonapoptotic neurodegeneration in
transgenic mice expressing human P301S tau protein, J. Neurosci. 22 (2002)
9340–9351.
[2] C. Ballard, et al., Alzheimer's disease, Lancet 377 (2011) 1019–1031.
[3] K. Bhaskar, et al., Tyrosine phosphorylation of tau accompanies disease progression
in transgenic mouse models of tauopathy, Neuropathol. Appl. Neurobiol. 36 (2010)
462–477.
[4] T. Bittner, et al., Multiple events lead to dendritic spine loss in triple transgenic
Alzheimer's disease mice, PLoS ONE 5 (2010) e15477.
[5] J. Boehm, A 'danse macabre': tau and Fyn in STEP with amyloid beta to facilitate
induction of synaptic depression and excitotoxicity, Eur. J. Neurosci. 37 (2013)
1925–1930.
[6] M.A. Chabrier, et al., Synergistic effects of amyloid-beta andwild-type human tau on
dendritic spine loss in a ﬂoxed double transgenic model of Alzheimer's disease,
Neurobiol. Dis. 64 (2014) 107–117.
[7] F. Chen, et al., Posttranslational modiﬁcations of tau - Role in human tauopathies
and modeling in transgenic animals, Curr. Drug Targets 5 (2004) 503–515.
[8] Q. Chen, et al., Tau protein is involved in morphological plasticity in hippocampal
neurons in response to BDNF, Neurochem. Int. 60 (2012) 233–242.
[9] M.E. Chicurel, K.M. Harris, Three-dimensional analysis of the structure and
composition of CA3 branched dendritic spines and their synaptic relationships
with mossy ﬁber boutons in the rat hippocampus, J. Comp. Neurol. 325 (1992)
169–182.
[10] J.N. Cochran, et al., The dendritic hypothesis for Alzheimer's disease pathophysiology,
Brain Res. Bull. 103 (2014) 18–28.
[11] N. Deters, et al., Divergent phosphorylation pattern of tau in P301L tau transgenic
mice, Eur. J. Neurosci. 28 (2008) 137–147.[12] T. Fath, et al., Primary support cultures of hippocampal and substantia nigra
neurons, Nat. Protoc. 4 (2009) 78–85.
[13] M.L. Frandemiche, et al., Activity-dependent tau protein translocation to excitatory
synapse is disrupted by exposure to amyloid-beta oligomers, J. Neurosci. 34
(2014) 6084–6097.
[14] J. Götz, et al., Somatodendritic localization and hyperphosphorylation of tau protein
in transgenic mice expressing the longest human brain tau isoform, EMBO J. 14
(1995) 1304–1313.
[15] I. Grundke-Iqbal, et al., Abnormal phosphorylation of the microtubule-associated
protein tau (tau) in Alzheimer cytoskeletal pathology, Proc. Natl. Acad. Sci. U. S. A.
83 (1986) 4913–4917.
[16] N.A. Hoffmann, et al., Impaired plasticity of cortical dendritic spines in P301S tau
transgenic mice, Acta Neuropathol. Commun. 1 (2013) 82.
[17] B.R. Hoover, et al., Tau mislocalization to dendritic spines mediates synaptic
dysfunction independently of neurodegeneration, Neuron 68 (2010) 1067–1081.
[18] M. Hundelt, et al., Altered phosphorylation but no neurodegeneration in a mouse
model of tau hyperphosphorylation, Neurobiol. Aging 32 (2009) 991–1006.
[19] L.M. Ittner, J. Götz, Amyloid-beta and tau - a toxic pas de deux in Alzheimer's
disease, Nat. Rev. Neurosci. 12 (2011) 65–72.
[20] L.M. Ittner, et al., Dendritic function of tau mediates amyloid-beta toxicity in
Alzheimer's disease mouse models, Cell 142 (2010) 387–397.
[21] S. Kins, et al., Activation of the ERK and JNK signaling pathways caused by neuron
speciﬁc inhibition of PP2A in transgenic mice, Am. J. Pathol. 163 (2003) 833–843.
[22] K.J. Kopeikina, et al., Tau causes synapse loss without disrupting calcium homeostasis
in the rTg4510 model of tauopathy, PLoS ONE 8 (2013) e80834.
[23] E.M. Kramer-Albers, R. White, From axon-glial signalling to myelination: the
integrating role of oligodendroglial Fyn kinase, Cell. Mol. Life Sci. 68 (2011)
2003–2012.
[24] P.N. Lacor, et al., Synaptic targeting by Alzheimer's-related amyloid beta oligomers, J.
Neurosci. 24 (2004) 10191–10200.
[25] M. Larson, et al., The complex PrP(c)-Fyn couples human oligomeric Abeta
with pathological tau changes in Alzheimer's disease, J. Neurosci. 32 (2012)
16857–16871a.
[26] H.A. Lashuel, et al., Themany faces of alpha-synuclein: from structure and toxicity to
therapeutic target, Nat. Rev. Neurosci. 14 (2013) 38–48.
[27] G. Lee, et al., Tau interacts with src-family non-receptor tyrosine kinases, J. Cell Sci.
111 (1998) 3167–3177.
[28] V.M. Lee, et al., Neurodegenerative tauopathies, Annu. Rev. Neurosci. 24 (2001)
1121–1159.
[29] G. Mairet-Coello, et al., The CAMKK2-AMPK kinase pathway mediates the
synaptotoxic effects of Abeta oligomers through Tau phosphorylation, Neuron 78
(2013) 94–108.
[30] G.R. Phillips, et al., The presynaptic particle web: ultrastructure, composition,
dissolution, and reconstitution, Neuron 32 (2001) 63–77.
[31] E. Sontag, et al., Regulation of the phosphorylation state and microtubule-binding
activity of Tau by protein phosphatase 2A, Neuron 17 (1996) 1201–1207.
[32] J.M. Sontag, et al., The protein phosphatase PP2A/Balpha binds to the microtubule-
associated proteins Tau and MAP2 at a motif also recognized by the kinase Fyn:
implications for tauopathies, J. Biol. Chem. 287 (2012) 14984–14993.
[33] K.E. Sorra, K.M. Harris, Overviewon the structure, composition, function, development,
and plasticity of hippocampal dendritic spines, Hippocampus 10 (2000) 501–511.
[34] P.L. Stein, et al., pp59fyn mutant mice display differential signaling in thymocytes
and peripheral T cells, Cell 70 (1992) 741–750.
[35] K.L. Tucker, et al., Neurotrophins are required for nerve growth during development,
Nat. Neurosci. 4 (2001) 29–37.
[36] A. Usardi, et al., Tyrosine phosphorylation of tau regulates its interactions with Fyn
SH2 domains, but not SH3 domains, altering the cellular localization of tau, FEBS J.
278 (2011) 2927–2937.
[37] D. Xia, J. Götz, Premature lethality, hyperactivity, and aberrant phosphorylation in
transgenic mice expressing a constitutively active form of Fyn, Front. Mol. Neurosci.
7 (2014) 40.
[38] H. Xu, et al., Memory deﬁcits correlate with Tau and spine pathology in P301SMAPT
transgenic mice, Neuropathol. Appl. Neurobiol. 40 (2014) 833–843.
[39] S.P. Zamora-Leon, et al., Binding of Fyn to MAP-2c through an SH3 binding domain.
Regulation of the interaction by ERK2, J. Biol. Chem. 276 (2001) 39950–39958.
[40] H. Zempel, et al., Amyloid-beta oligomers induce synaptic damage via Tau-
dependent microtubule severing by TTLL6 and spastin, EMBO J. 32 (2013)
2920–2937.
[41] H. Zempel, E. Mandelkow, Lost after translation: missorting of Tau protein and
consequences for Alzheimer disease, Trends Neurosci. 37 (2014) 721–732.
[42] H. Zempel, et al., Abeta oligomers cause localized Ca(2+) elevation, missorting of
endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtu-
bules and spines, J. Neurosci. 30 (2010) 11938–11950.
[43] Z. Zhang, et al., Cleavage of tau by asparagine endopeptidase mediates
the neuroﬁbrillary pathology in Alzheimer's disease, Nat. Med. 20 (2014)
1254–1262.
